Izoniazida Atb

Isoniazid, the active ingredient in Izoniazida Atb, is an antitubercular drug presented as an oral tablet (strength not specified) for systemic use. It is employed in the treatment and prevention of Mycobacterium tuberculosis infection in both adults and children, typically as part of multi‑drug regimens.

GNH USA supplies Izoniazida Atb as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with distribution originating from the European Union market, ensuring quality and regulatory compliance.

Isoniazid is used in the antitubercular therapeutic class to combat Mycobacterium tuberculosis infection.

Tuberculosis: Treats active pulmonary and extrapulmonary TB as part of combination therapy. Latent TB infection: Provides prophylaxis for individuals with recent exposure to TB. Preventive therapy: Used in high‑risk contacts to reduce progression to active disease.

Isoniazid may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea or vomiting - Loss of appetite - Mild peripheral neuropathy - Elevated liver enzymes - Rash or itching - Fatigue

Serious or Rare Side Effects: - Hepatotoxicity, including hepatitis - Severe peripheral neuropathy - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Anemia or other hematologic abnormalities

Before initiating therapy, consider the following safety measures.

Baseline liver function testing: assess hepatic enzymes to detect pre‑existing liver disease. Alcohol consumption: limit intake, as alcohol increases hepatotoxic risk. Vitamin B6 supplementation: co‑administer pyridoxine to reduce neuropathy, especially in malnourished patients. Pregnancy and lactation: evaluate risk‑benefit ratio; use only if clearly needed. Drug resistance monitoring: ensure adherence to combination regimens to prevent resistance. Store at ambient temperature: keep below 25°C in the original container, protect from moisture and direct sunlight.

Isoniazid can affect the pharmacokinetics of several co‑administered medicines.

Major Interactions (Avoid): - Rifampicin: reduces isoniazid plasma levels, compromising efficacy. - Phenytoin: may increase hepatotoxic risk when combined.

Moderate Interactions (Monitor Closely): - Acetylsalicylic acid (aspirin): may enhance liver enzyme elevation. - Valproic acid: potential for increased hepatic toxicity; monitor liver function regularly.